Lonza Group Delivers Strong Q1 2026 Performance & Confirms Full-Year Outlook
Key Highlights for Investors
- Robust Q1 2026 Performance: Lonza Group reported strong performance across its CDMO business, in line with expectations and its full-year trajectory. The company’s sales growth and CORE EBITDA margin were notably stronger in the first half of 2026 due to favorable campaign timing, product releases, and planned site shutdowns.
- Transformation to Pure-Play CDMO: Lonza successfully completed its strategic transformation to a pure-play CDMO with the signing of an agreement to divest its Capsules & Health Ingredients (CHI) business. The company also divested three other non-core businesses: Personalized Medicines (including the Cocoon® platform), the MODA® software platform, and the small molecules micronization site in Monteggio (CH).
- Investment & Expansion: Major ramp-up activities are underway at Lonza’s large-scale mammalian facility in Visp (CH), with full commercial operations expected to commence in mid-2026. Construction is progressing at Stein (CH) for an aseptic drug product facility and at Visp for a large-scale bioconjugation facility (operations expected in 2027 and 2028). First investments to increase operational flexibility at Vacaville (US) are underway, with strong progress anticipated in 2026.
- Strong Commercial Demand: Multiple integrated drug substance-drug product contracts were secured in Q1 2026, including an extension of the commercial manufacturing agreement for Genetix’s ZYNTEGLO™. Customer interest in Lonza’s Vacaville mammalian capacity remains high, supporting expectations for peak sales in the early 2030s.
- Financial Outlook: Lonza confirmed its 2026 outlook with 11-12% CER sales growth and further CORE EBITDA margin expansion, targeting a level above 32%. The company expects stronger sales growth and margins in H1 2026 compared to H2 2026. Beyond 2026, Lonza anticipates low teens percentage CER sales growth, with CORE EBITDA growth ahead of sales.
- Shareholder Returns: Following the CHI sale, Lonza will return CHF 500 million in surplus capital via an expedited share buyback program, expected in Q3 2026.
- Resilience Against Geopolitical & Macro Risks: Lonza is well-hedged against energy price volatility for 2026 and has limited exposure to the Middle East. No material impact is expected from recent US trade and tariff policies, or from recent geopolitical conflicts.
- Capsules & Health Ingredients Business: For discontinued operations, Lonza expects mid-single-digit CER sales growth and further CORE EBITDA margin expansion in 2026.
Details Investors Should Know
- Transformation & Divestment: The transformation to a pure-play CDMO is a major strategic move. The CHI divestment to Lone Star Funds (signed March 2026) will deliver CHF 1.7 billion in upfront proceeds, a retained 40% stake, and preferential participation in a future exit. Proceeds will fund organic growth and bolt-on acquisitions, supporting Lonza’s One Lonza strategy to expand capacities and technologies.
- Portfolio Streamlining: The closure of divestments in Personalized Medicines, MODA® software, and small molecules micronization completes the portfolio adjustment. Lonza now operates through three highly integrated business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, leveraging the Lonza Engine®.
- Growth Projects: Growth in Integrated Biologics is driven by project ramp-ups and strong execution. Advanced Synthesis benefits from the rapid ramp-up of projects started in 2025, favorable product mix, and early batch releases. Specialized Modalities saw significant growth, especially in the Microbial business and Bioscience.
- FX Impact: Lonza anticipates an FX headwind of approximately -3.0% on sales in 2026, mainly due to the US Dollar’s weakness in 2025. Margins are minimally impacted due to Lonza’s hedging programs.
- Resilience & Risk Management: Lonza’s risk diversification across products, customers, and technologies mitigates exposure to geopolitical and macroeconomic volatility. Energy needs for 2026 are mostly hedged, and a sizeable share is secured for 2027.
- Industry Dynamics: Lonza notes sustained outsourcing demand from large pharma and biotech companies, despite possible delays in outsourcing decisions following significant US investments by large pharmaceutical companies. These investments are seen as a shift in global CapEx spend toward the US, rather than fundamental changes in sourcing strategies.
Potential Price Sensitive News
- CHI Divestment & Share Buyback: The CHI business sale will result in significant proceeds and a planned buyback of CHF 500 million in shares, which may positively affect share value.
- Confirmed Outlook & Margin Expansion: Confirmation of strong sales growth and margin expansion above 32% for 2026 could be positive for investor sentiment.
- Strategic Expansion Projects: Progress at Visp, Stein, and Vacaville sites, and the securing of high-value contracts, indicate strong future growth prospects, which may impact share price.
- Risk Mitigation: Lonza’s proactive risk management and limited exposure to recent geopolitical and trade developments reduce downside risks for shareholders.
About Lonza
Lonza is the world’s largest contract development and manufacturing organization (CDMO) dedicated to the healthcare industry. With a global team of approximately 20,000 colleagues, Lonza works with pharma and biotech companies to bring breakthrough innovations to patients. In 2025, Lonza generated sales of CHF 6.5 billion and a CORE EBITDA of CHF 2.1 billion.
Contact Information
- Daniel Buchta, Head of Investor Relations, Lonza Group Ltd, Tel +41 61 316 29 85, [email protected]
- Victoria Morgan, Head of External Communications, Lonza Group Ltd, Tel +41 61 316 22 83, [email protected]
Disclaimer
This article contains information derived from Lonza Group’s Q1 2026 business update and outlook. Certain statements may constitute forward-looking statements and are based on current expectations and estimates. Actual results may differ materially due to various factors. Investors are cautioned that all forward-looking statements involve risks and uncertainty. This article is for informational purposes only and does not constitute investment advice.
